



## Clinical trial results:

### Senicapoc in COVID-19 Patients with Severe Respiratory Insufficiency – A Randomized, Open-Label, Phase II Trial

#### Summary

|                          |                  |
|--------------------------|------------------|
| EudraCT number           | 2020-001420-34   |
| Trial protocol           | DK               |
| Global end of trial date | 28 December 2020 |

#### Results information

|                                |                 |
|--------------------------------|-----------------|
| Result version number          | v1 (current)    |
| This version publication date  | 21 January 2022 |
| First version publication date | 21 January 2022 |

#### Trial information

##### Trial identification

|                       |      |
|-----------------------|------|
| Sponsor protocol code | 0001 |
|-----------------------|------|

##### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT04594668 |
| WHO universal trial number (UTN)   | -           |

Notes:

##### Sponsors

|                              |  |
|------------------------------|--|
| Sponsor organisation name    | Aarhus University  |
| Sponsor organisation address | Ole Worms Allé 4, Building 1160, Aarhus C, Denmark, 8000                 |
| Public contact               | www.Clinicaltrials.gov, Aarhus University, +45 60202613, us@biomed.au.dk |
| Scientific contact           | www.Clinicaltrials.gov, Aarhus University, +45 60202613, us@biomed.au.dk |

Notes:

##### Paediatric regulatory details

|  |    |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

---

**Results analysis stage**

---

|  |                   |
|--|-------------------|
| Analysis stage                                       | Final             |
| Date of interim/final analysis                       | 30 September 2021 |
| Is this the analysis of the primary completion data? | Yes               |
| Primary completion date                              | 28 December 2020  |
| Global end of trial reached?                         | Yes               |
| Global end of trial date                             | 28 December 2020  |
| Was the trial ended prematurely?                     | No                |

Notes:

---

**General information about the trial**

---

Main objective of the trial:

To treat respiratory insufficiency due to COVID19

Protection of trial subjects:

The study was IDMC monitored. Patients were admitted to the ICU and the intervention did not include additional stress or pain

Background therapy: -

Evidence for comparator: -

|   |               |
|---|---------------|
| Actual start date of recruitment                          | 28 April 2020 |
| Long term follow-up planned                               | No            |
| Independent data monitoring committee (IDMC) involvement? | Yes           |

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

|                                      |             |
|--------------------------------------|-------------|
| Country: Number of subjects enrolled | Denmark: 46 |
| Worldwide total number of subjects   | 46          |
| EEA total number of subjects         | 46          |

Notes:

---

**Subjects enrolled per age group**

---

|   |    |
|---|----|
| In utero                                  | 0  |
| Preterm newborn - gestational age < 37 wk | 0  |
| Newborns (0-27 days)                      | 0  |
| Infants and toddlers (28 days-23 months)  | 0  |
| Children (2-11 years)                     | 0  |
| Adolescents (12-17 years)                 | 0  |
| Adults (18-64 years)                      | 21 |
| From 65 to 84 years                       | 25 |
| 85 years and over                         | 0  |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Patients were included if they were aged  $\geq 18$  years and admitted to an ICU with severe respiratory insufficiency due to COVID-19. COVID-19 was defined as a positive polymerase chain reaction (PCR) test for SARS-CoV-2, within 14 days prior to ICU admission. Severe respiratory insufficiency was defined as requiring supplemental oxygen  $\geq 10$  L/min or m

### Period 1

|                              |                               |
|------------------------------|-------------------------------|
| Period 1 title               | Entire study (overall period) |
| Is this the baseline period? | Yes                           |
| Allocation method            | Randomised - controlled       |
| Blinding used                | Not blinded                   |

### Arms

|                              |               |
|------------------------------|---------------|
| Are arms mutually exclusive? | Yes           |
| <b>Arm title</b>             | Control group |

Arm description:

Control group

|   |                 |
|---|-----------------|
| Arm type  | No intervention |
| No investigational medicinal product assigned in this arm |                 |

|                  |                 |
|------------------|-----------------|
| <b>Arm title</b> | Senicapoc group |
|------------------|-----------------|

Arm description:

Senicapoc group

|  |                  |
|--|------------------|
| Arm type                               | Experimental     |
| Investigational medicinal product name | Senicapoc        |
| Investigational medicinal product code |                  |
| Other name                             |                  |
| Pharmaceutical forms                   | Tablet           |
| Routes of administration               | Intragastric use |

Dosage and administration details:

The intervention consisted of 50 mg enteral senicapoc (5 x 10 mg tablets) administered as soon as possible after randomization and again after 24 hours.

| <b>Number of subjects in period 1</b> | Control group | Senicapoc group |
|---------------------------------------|---------------|-----------------|
| Started                               | 26            | 20              |
| Completed                             | 26            | 20              |

## Baseline characteristics

### Reporting groups

|                              |                 |
|------------------------------|-----------------|
| Reporting group title        | Control group   |
| Reporting group description: |                 |
| Control group                |                 |
| Reporting group title        | Senicapoc group |
| Reporting group description: |                 |
| Senicapoc group              |                 |

| Reporting group values                             | Control group | Senicapoc group | Total |
|--|---------------|-----------------|-------|
| Number of subjects                                 | 26            | 20              | 46    |
| Age categorical                                    |               |                 |       |
| Units: Subjects                                    |               |                 |       |
| In utero   |               |                 | 0     |
| Preterm newborn infants (gestational age < 37 wks) |               |                 | 0     |
| Newborns (0-27 days)                               |               |                 | 0     |
| Infants and toddlers (28 days-23 months)           |               |                 | 0     |
| Children (2-11 years)                              |               |                 | 0     |
| Adolescents (12-17 years)                          |               |                 | 0     |
| Adults (18-64 years)                               |               |                 | 0     |
| From 65-84 years                                   |               |                 | 0     |
| 85 years and over                                  |               |                 | 0     |
| Age continuous                                     |               |                 |       |
| Age  |               |                 |       |
| Units: years                                       |               |                 |       |
| median   | 66            | 66              |       |
| inter-quartile range (Q1-Q3)                       | 56 to 74      | 58 to 70        | -     |
| Gender categorical                                 |               |                 |       |
| Gender   |               |                 |       |
| Units: Subjects                                    |               |                 |       |
| Female   | 6             | 10              | 16    |
| Male   | 20            | 10              | 30    |

## End points

### End points reporting groups

|                              |                 |
|------------------------------|-----------------|
| Reporting group title        | Control group   |
| Reporting group description: |                 |
| Control group                |                 |
| Reporting group title        | Senicapoc group |
| Reporting group description: |                 |
| Senicapoc group              |                 |

### Primary: The PaO<sub>2</sub>/FiO<sub>2</sub> ratio

|  |  |
|--|--|
| End point title  | The PaO <sub>2</sub> /FiO <sub>2</sub> ratio |
| End point description:                                   |  |
| The PaO <sub>2</sub> /FiO <sub>2</sub> ratio at 72 hours |  |
| End point type   | Primary                                      |
| End point timeframe:                                     |  |
| at 72 hours  |  |

| End point values                     | Control group   | Senicapoc group |  |  |
|--------------------------------------|-----------------|-----------------|--|--|
| Subject group type                   | Reporting group | Reporting group |  |  |
| Number of subjects analysed          | 26              | 20              |  |  |
| Units: mmHg                          |                 |                 |  |  |
| arithmetic mean (standard deviation) | 24.4 (± 9.6)    | 19.5 (± 6.6)    |  |  |

### Statistical analyses

|   |                                 |
|---|---------------------------------|
| Statistical analysis title              | Primary outcome                 |
| Comparison groups                       | Control group v Senicapoc group |
| Number of subjects included in analysis | 46                              |
| Analysis specification                  | Pre-specified                   |
| Analysis type                           | superiority <sup>[1]</sup>      |
| P-value                                 | < 0.05                          |
| Method                                  | Regression, Linear              |
| Parameter estimate                      | Mean difference (final values)  |
| Point estimate                          | -5.1                            |
| Confidence interval                     |                                 |
| level                                   | 95 %                            |
| sides                                   | 2-sided                         |
| lower limit                             | -10.2                           |
| upper limit                             | 0.04                            |

Notes:

[1] - linear regression adjusting for the two stratification variables (baseline PaO<sub>2</sub>/FiO<sub>2</sub> ratio and site) as fixed effects

## Secondary: Mortality

|                        |           |
|------------------------|-----------|
| End point title        | Mortality |
| End point description: | Mortality |
| End point type         | Secondary |
| End point timeframe:   | 28 days   |

|                             |                 |                 |  |  |
|-----------------------------|-----------------|-----------------|--|--|
| <b>End point values</b>     | Control group   | Senicapoc group |  |  |
| Subject group type          | Reporting group | Reporting group |  |  |
| Number of subjects analysed | 26              | 20              |  |  |
| Units: %                    | 6               | 2               |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Ventilator free hours

|                        |                                     |
|------------------------|-------------------------------------|
| End point title        | Ventilator free hours               |
| End point description: |                                     |
| End point type         | Secondary                           |
| End point timeframe:   | ventilator-free days within 28 days |

|                                       |                 |                  |  |  |
|---------------------------------------|-----------------|------------------|--|--|
| <b>End point values</b>               | Control group   | Senicapoc group  |  |  |
| Subject group type                    | Reporting group | Reporting group  |  |  |
| Number of subjects analysed           | 26              | 20               |  |  |
| Units: day                            |                 |                  |  |  |
| median (inter-quartile range (Q1-Q3)) | 486 (0 to 672)  | 607 (398 to 672) |  |  |

## Statistical analyses

|                                   |                                 |
|-----------------------------------|---------------------------------|
| <b>Statistical analysis title</b> | Ventilator free hours           |
| Comparison groups                 | Senicapoc group v Control group |

|   |                         |
|---|-------------------------|
| Number of subjects included in analysis | 46                      |
| Analysis specification                  | Pre-specified           |
| Analysis type                           | superiority             |
| P-value                                 | < 0.05                  |
| Method                                  | Wilcoxon (Mann-Whitney) |

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Study period

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |                  |
|-----------------|------------------|
| Dictionary name | Specific adverse |
|-----------------|------------------|

|                    |   |
|--------------------|---|
| Dictionary version | 1 |
|--------------------|---|

### Reporting groups

|                       |               |
|-----------------------|---------------|
| Reporting group title | Control group |
|-----------------------|---------------|

Reporting group description: -

|                       |           |
|-----------------------|-----------|
| Reporting group title | Senicapoc |
|-----------------------|-----------|

Reporting group description: -

| Serious adverse events                            | Control group    | Senicapoc        |  |
|---|------------------|------------------|--|
| Total subjects affected by serious adverse events |                  |                  |  |
| subjects affected / exposed                       | 22 / 26 (84.62%) | 10 / 20 (50.00%) |  |
| number of deaths (all causes)                     | 6                | 2                |  |
| number of deaths resulting from adverse events    | 0                | 0                |  |
| Cardiac disorders                                 |                  |                  |  |
| arrhythmias                                       |                  |                  |  |
| subjects affected / exposed                       | 6 / 26 (23.08%)  | 2 / 20 (10.00%)  |  |
| occurrences causally related to treatment / all   | 0 / 6            | 0 / 2            |  |
| deaths causally related to treatment / all        | 0 / 0            | 0 / 0            |  |
| Shock   |                  |                  |  |
| subjects affected / exposed                       | 4 / 26 (15.38%)  | 1 / 20 (5.00%)   |  |
| occurrences causally related to treatment / all   | 0 / 4            | 0 / 1            |  |
| deaths causally related to treatment / all        | 0 / 0            | 0 / 0            |  |
| Endocrine disorders                               |                  |                  |  |
| Hyperglycaemia                                    |                  |                  |  |
| subjects affected / exposed                       | 7 / 26 (26.92%)  | 5 / 20 (25.00%)  |  |
| occurrences causally related to treatment / all   | 0 / 7            | 0 / 5            |  |
| deaths causally related to treatment / all        | 0 / 0            | 0 / 0            |  |

Frequency threshold for reporting non-serious adverse events: 0 %



| <b>Non-serious adverse events</b>                     | Control group   | Senicapoc      |  |
|---|-----------------|----------------|--|
| Total subjects affected by non-serious adverse events |                 |                |  |
| subjects affected / exposed                           | 3 / 26 (11.54%) | 1 / 20 (5.00%) |  |
| Blood and lymphatic system disorders                  |                 |                |  |
| Anaemia   |                 |                |  |
| subjects affected / exposed                           | 3 / 26 (11.54%) | 1 / 20 (5.00%) |  |
| occurrences (all)                                     | 3               | 1              |  |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported